Article
Medicine, General & Internal
Chunyan Wei, Wanhong Yin, Zhiyao He, Bin Wu
Summary: This study evaluated the muscular toxicity of the combination therapy of daptomycin and statins using a large pharmacovigilance database. The results showed that the combination of daptomycin with rosuvastatin, atorvastatin, and simvastatin increased the reporting frequency of myopathy. Additionally, the combination of daptomycin with these statins also increased the frequency of rhabdomyolysis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Blanca Gavilan-Carrera, Alberto Soriano-Maldonado, Juan Diego Mediavilla-Garcia, Carl J. Lavie, Jose Antonio Vargas-Hitos
Summary: Statin-associated muscle symptoms (SAMS) are common in patients using statin drugs, but not all symptoms are caused by the drugs, negative expectations could also play a role. Physical activity is important for managing cardiovascular disease risk, but the evidence of increased creatine-kinase levels in statin-treated athletes has been wrongly generalized. The potential of reducing sedentary behavior and resistance training has been overlooked in current guidelines.
PHARMACOLOGICAL RESEARCH
(2023)
Review
Cardiac & Cardiovascular Systems
Mahmoud Al Rifai, Roger S. Blumenthal, Neil J. Stone, Richard S. Scho, Carl Edward Orringer, Erin D. Michos, Paul A. Heidenreich, Lynne Braun, Kim K. Birtcher, Sidney C. Smith, Vijay Nambi, Scott Grundy, Salim S. Virani
Summary: This review compares the cholesterol guidelines of two major American organizations and reviews the evidence base used to generate recommendations focusing on 4 themes. The different conclusions reached by the two organizations on key issues are discussed.
PROGRESS IN CARDIOVASCULAR DISEASES
(2021)
Review
Biochemistry & Molecular Biology
Saeed Aslani, Bahman Razi, Danyal Imani, Keyhan Mohammadi, Tannaz Jamialahmadi, Zeljko Reiner, Amirhossein Sahebkar
Summary: A systematic review and meta-analysis showed that statin therapy effectively lowered levels of total cholesterol, LDL-C, and TG, and increased levels of HDL-C in patients with different CVDs.
CURRENT MEDICINAL CHEMISTRY
(2023)
Article
Medicine, Research & Experimental
Georgia Anastasiou, Eftihia Sakka, Efi Blathra, Anna Kalivi, Moses Elisaf, George Liamis, Evangelos Liberopoulos
Summary: This retrospective study analyzed patients with Lp(a) levels >= 30 mg/dL at the University of Ioannina Hospital Lipid Clinic, revealing a significant proportion of patients with cardiovascular diseases, familial hypercholesterolemia, and positive family history of early ASCVD. Lipid-lowering therapy was effective in reducing LDL-C levels in different patient groups.
ARCHIVES OF MEDICAL RESEARCH
(2021)
Article
Multidisciplinary Sciences
Ji Bak Kim, Woo Hyuk Song, Jong Sung Park, Tae-Jin Youn, Yong Hyun Park, Shin-Jae Kim, Sung Gyun Ahn, Joon-Hyung Doh, Yun-Hyeong Cho, Jin Won Kim
Summary: In high-risk Asian patients with hypercholesterolemia, atorvastatin 20 mg was more effective in reducing LDL-C and more cost-effective compared to atorvastatin 10 mg.
Article
Biochemistry & Molecular Biology
Yvette L. Schooneveldt, Corey Giles, Michael F. Keating, Natalie A. Mellett, Aaron W. Jurrjens, Sudip Paul, Anna C. Calkin, Peter J. Meikle
Summary: The study found that altering cholesterol conditions affects the lipidome of liver cells, including increased levels of lipids containing arachidonic acid and decreases in phosphatidylinositol species. The PI(36:2)/PC(18:0_20:4) ratio responds to changes in intracellular cholesterol abundance, likely through a flux of the n-6 fatty acid pathway and altered phosphatidylinositol synthesis.
Review
Medicine, General & Internal
Julia L. Newton, Joseph Hamed, Helen Williams, Matt Kearney, Alison M. Metcalfe, Gary A. Ford
Summary: This study aimed to understand the impact of the COVID-19 pandemic on prescribing lipid-lowering therapy in England, as a potential cause of increased cardiovascular mortality post-pandemic. The study found a significant reduction in the prescribing of high-intensity and non-high-intensity statin therapy and ezetimibe during the COVID-19 pandemic. Urgent action is needed to reverse and improve the impact of the pandemic on cholesterol optimization and historical undertreatment of cholesterol to prevent worsening cardiovascular risk in the future.
BRITISH MEDICAL BULLETIN
(2023)
Article
Clinical Neurology
Osorio Lopes Abath Neto, Livija Medne, Sandra Donkervoort, Maria Elena Rodriguez-Garcia, Veronique Bolduc, Ying Hu, Eleonora Guadagnin, A. Reghan Foley, John F. Brandsema, Allan M. Glanzman, Gihan Tennekoon, Mariarita Santi, Justin H. Berger, Lynn A. Megeney, Hirofumi Komaki, Michio Inoue, Francisco Javier Cotrina-Vinagre, Aurelio Hernandez-Lain, Elena Martin-Hernandez, Linford Williams, Sabine Borell, David Schorling, Kimberly Lin, Konstantinos Kolokotronis, Uta Lichter-Konecki, Janbernd Kirschner, Ichizo Nishino, Brenda Banwell, Francisco Martinez-Azorin, Patrick G. Burgon, Carsten G. Bonnemann
Summary: This study identified seven individuals from six families with biallelic variants in the MLIP gene, shedding light on the genetic landscape of rhabdomyolysis. The findings solidify MLIP's role in maintaining normal and diseased skeletal muscle homeostasis.
Article
Cardiac & Cardiovascular Systems
Ciaran N. Kohli-Lynch, Brandon K. Bellows, Yiyi Zhang, Bonnie Spring, Dhruv S. Kazi, Mark J. Pletcher, Eric Vittinghoff, Norrina B. Allen, Andrew E. Moran
Summary: The study revealed that around 27% of ASCVD-free young adults in the United States have LDL-C levels >_130 mg/dL, and 9% have LDL-C >_160 mg/dL. Using statins or lifestyle interventions for lipid-lowering can prevent ASCVD events and increase QALYs compared to standard care.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Sonia Sawant, Nelson Wang
Summary: This study found that lipid-lowering therapy (LLT) has similar cardiovascular event reduction effects across different ethnicities and regions, highlighting the importance of promoting LLT in at-risk populations.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Endocrinology & Metabolism
Lufan Sun, Anna Wolska, Marcelo Amar, Rafael Zubiran, Alan T. Remaley
Summary: This article introduces the lipid-lowering therapy of statins in the prevention of atherosclerotic cardiovascular disease (ASCVD), but their effectiveness in lowering LDL-C can vary significantly between individuals. The different causes of a suboptimal statin response are described, and an algorithm for the diagnosis and clinical management of these patients is provided.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Biochemistry & Molecular Biology
Braulio Valdebenito-Maturana, Franco Valdebenito-Maturana, Monica Carrasco, Juan Carlos Tapia, Alejandro Maureira
Summary: High cholesterol levels are associated with a high risk of cardiovascular diseases, making it critical to lower cholesterol levels through pharmacological care. Statin therapy, while beneficial, can cause skeletal muscle disorders. The mechanisms behind these side effects are unknown.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Mauro Vaccarezza, Francesco Maria Galassi
Summary: Despite advancements in standard care, cardiovascular diseases remain the leading cause of death worldwide. Atherosclerosis is the main culprit behind heart attacks, strokes, and peripheral vascular diseases, imposing significant burdens on life expectancy, quality of life, morbidity, and costs. Elevated cholesterol levels and inflammation have been recognized as cardiovascular risk factors, and recent research highlights the role of inflammation in determining cardiovascular risk independent of cholesterol levels and treatments.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Cardiac & Cardiovascular Systems
Kartik Gupta, Tanya S. Kakar, Vardhmaan Jain, Mohak Gupta, Mahmoud Al Rifai, Leandro Slipczuk, Vijay Nambi, Vera Bittner, Roger S. Blumenthal, Neil J. Stone, Carl J. Lavie, Salim S. Virani
Summary: The United States Preventive Services Taskforce (USPSTF) has recently released recommendations for statin therapy for the primary prevention of cardiovascular disease. According to these recommendations, approximately 31.8% of US adults would be eligible for statin therapy. This is a smaller proportion compared to the previously published 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol guidelines.
PROGRESS IN CARDIOVASCULAR DISEASES
(2022)